A Phase 2 interventional study of transdermal 17β-E2 with cyclic progestin and oral 17β-E2 with cyclic progestin in Bone Strength, Bone Density and FHA (Functional Hypothalamic Amenorrhea), sponsored by University of Virginia. Recruiting at 2 sites in United States. Open to female participants aged 14 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-07-17.
Sponsored by University of Virginia · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Amenorrhea with a site in United States — 7 open to participants now, 9 under way, 1 of them phase 3. Amenorrhea · United States.
Among the 43 studies in Amenorrhea with a site in United States, this one is the 6th largest by planned enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2025, is one of 9 in phase 2, and was the 40th registered.
80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.
Browse Amenorrhea studies →7 of the 43 studies in Amenorrhea with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–40 · Women only
Massachusetts General Hospital · Sites in United States
Ages 14–30 · Women only
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 8–99
University of Colorado, Colorado Springs · Sites in United States
Ages 18–35 · Women only · Healthy volunteers
Cornell University · Sites in United States
Ages 9–17 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Amenorrhea studies recruiting now, none (0%) set no upper age limit and 11 (85%) stop at 75 or younger; 8 take children under 18; 3 take healthy volunteers.
This study: 14 Years to 30 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 6 · Phase 4 2
First in 1989; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 54 across 49 interventional studies indexed under Amenorrhea.
Median enrollment 37 across the 30 interventional studies, 111 across the 13 observational. Of the 28 that completed or were terminated, 13 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 43 have an industry lead sponsor. The 10 most frequent:
University of Virginia is the lead sponsor of 677 studies on the registry; 139 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 42 (69%) have results posted.
University of Virginia has 1 study filed under Amenorrhea — fewer than ten, so there is no comparison to draw.
2 of the studies in Amenorrhea with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00589654Memorial Sloan Kettering Cancer CenterMenstrual Cycle Maintenance and Quality of Life: A Prospective Study | 2026-12 |
| NCT05629377Mayo ClinicHypothalamic Amenorrhea as a Fertility Status Marker for Cardiovascular Health (ARCH) | 2026-12-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies in Amenorrhea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess whether the natural form of estrogen (17-beta estradiol) given as a patch so that it is absorbed through your skin, is better at improving bone strength over 1 year than natural estrogen (17-beta estradiol) taken by mouth, or a synthetic form oestrogen (ethinyl estradiol) given as a patch that also provides birth control.
Participants will:
Attend 4 study visits over 12 months with two at the beginning and then every 6 months that include:
Low bone mass is a major co-morbid complication of functional hypothalamic amenorrhea (FHA) in adolescents and young adult women, including those with anorexia nervosa (AN) and exercise-induced amenorrhea (EIA), and the prevalence of fractures is markedly higher than in normal-weight controls (43% in EIA, 38% in AN vs. 22% in controls).1 Adolescence and young adulthood are a critical time for bone accrual. Peak bone mass, a major determinant of bone mineral density (BMD) and fracture risk in adult life, is established between 20-25 years of age in women. Insults to bone accrual during the adolescent and young adult years could result in permanent bone mass deficits, leading to increases in fracture risk. Despite weight regain and menses recovery in some individuals, BMD remains lower than in normal-weight peers, likely because weight recovery is often partial, relapses are common, and not all hormonal alterations contributing to low BMD in FHA completely normalize.2, 3 Thus, additional intervention is necessary to optimize skeletal health.
While many factors contribute to impaired skeletal health in FHA, a key contributor is the associated hypogonadism. Estrogen has anti-resorptive effects on bone through increases in osteoprotegerin and decreases in RANKL and inflammatory cytokines, and bone anabolic effects through inhibition of sclerostin. Yet, estrogen administration as the oral combined estrogen-progestin contraceptive pill is not effective in improving skeletal health4-6 because of hepatic first pass effects resulting in reduction in IGF-1 (a key bone trophic hormone, particularly during adolescence), and increases in SHBG (binding protein of the sex steroids), with a reduction in bioavailable estrogen.6, 7 In contrast, Investigators have demonstrated that transdermal physiologic 17β-estradiol replacement (17β-E2) (with cyclic progestin), which bypasses hepatic first pass metabolism and does not decrease IGF-1 or increase SHBG, increases bone accrual in adolescents and young adults with AN8 and EIA,6 resulting in its incorporation into Endocrine Society Guidelines for FHA management9.
However, transdermal 17β-E2 (with cyclic progesterone) does not have contraceptive efficacy and is not suitable for sexually active young women, unless administered with another mode of contraception (e.g. a progestin releasing IUD), and not always desirable to young women, leading to reduced uptake. The transdermal contraceptive patch containing a non-physiologic form of estrogen (ethinyl estradiol, EE) with a progestin (levonorgestrel, LNG) offers a systemic route of estrogen administration with avoidance of hepatic first pass metabolism. However, it is not known whether this patch is effective in improving skeletal health in FHA. Limited available data suggest otherwise,10 possibly because of an increase in SHBG with EE, despite transdermal administration.11-13 Further, many women prefer an oral pill because of skin irritation with the patch, cosmetic issues, and difficulty remembering to change the patch once or twice a week vs. taking a pill daily. While combined oral contraceptive pills containing EE are not effective in improving bone outcomes, it is not clear whether oral 17β-E2 (a physiologic form of estrogen) could be as effective as transdermal 17β-E2 despite hepatic first pass metabolism. Importantly, oral and transdermal 17β-E2 are often used interchangeably in other hypogonadal states,14 despite some evidence that oral 17β-E2 suppresses IGF-1 and increases SHBG.15, 16 The investigators thus propose a randomized controlled trial (RCT) of 2 mg oral 17β-E2 (with cyclic progesterone) vs. 100 mcg transdermal 17β-E2 (with cyclic progesterone) vs. 30 mcg transdermal EE (with LNG) in young women 14-25 years old with FHA (who are in the process of accruing peak bone mass) to determine whether transdermal 17β-E2 is more effective than oral 17β-E2 or transdermal EE in improving bone outcomes, or whether one or both of the latter two modes of estrogen administration are equivalent to transdermal 17β-E2 in this context. Results from this study could markedly impact clinical management of young women with FHA and potentially allow for alternative forms of estrogen administration in those with FHA.
Aim 1: To characterize the impact of transdermal 17β-E2 (with cyclic progesterone) vs. oral 17β-E2 (with cyclic progesterone) and transdermal EE (with LNG) on bone geometry, structure, density and strength in young women 14-25 years old with functional hypothalamic amenorrhea. Investigators hypothesize that transdermal 17β-E2 will be superior to oral 17β-E2 and transdermal EE in achieving optimal improvement in:
Hypothesis 1A: Areal BMD at the spine, hip and femoral neck; spine trabecular bone score (DXA)
Hypothesis 1B: Volumetric BMD, bone geometry and structure at the distal radius and tibia (HRpQCT)
Hypothesis 1C: Bone strength estimates (assessed using microfinite element analysis)
Aim 2: To determine effects of transdermal 17β-E2 (with cyclic progesterone) vs. oral 17β-E2 (with cyclic progesterone) and transdermal EE+LNG on levels of IGF-1 and SHBG, in relation to markers of bone turnover. Investigators hypothesize that:
Hypothesis 2A: Compared to transdermal 17β-E2, oral 17β-E2 will cause greater decreases in IGF-1, and both oral 17β-E2 and transdermal EE will cause greater increases in SHBG (with decreases in bioavailable estradiol).
Hypothesis 2B: Those with greater decreases in IGF-1 and greater increases in SHBG will demonstrate greater decreases in a bone formation marker (N-terminal propeptide of Type 1 procollagen, P1NP); changes in P1NP will be associated positively with changes in bone variables.
Data resulting from the study will be instrumental in driving recommendations for estrogen replacement in FHA.
Design: 114 young women 14-30 years old with FHA will be randomized in a 1:1:1 fashion to 1 of 3 groups for 12 months (1) 100 mcg transdermal 17β-E2 (with cyclic progesterone) OR (2) 2 mg oral 17β-E2 (with cyclic progesterone) OR (3) transdermal EE+LNG, to determine whether transdermal 17β-E2 is more effective than oral 17β-E2 or transdermal EE in improving bone outcomes, or whether one or both of the latter two modes of estrogen administration are equivalent to transdermal 17β-E2 in this context. All participants with FHA will also receive at least 600 IU of vitamin D and 1000 mg of calcium daily to avoid effects of suboptimal vitamin D concentrations and calcium status on bone endpoints. The study will be randomized, but not blinded (i) because there is a risk of participants assuming they are receiving contraception (with a blinded design) resulting in accidental pregnancies, and (ii) because bone outcomes (unlike e.g. psychological outcomes) are not expected to be impacted by study blinding/unblinding.
Analytical Plan:
The study will be done as intention-to-treat, analyzing changes in bone health at 12 months among participants randomized to the treatment groups. In general, the safety and efficacy populations will be the same, namely, all participants randomized to a treatment.
Participant characteristics at the time of randomization will be tabulated by group. Categorical variables will be summarized by percentages; continuous variables will be summarized by medians and interquartile ranges. No inferential statistical are planned.
Analysis of Aim 1:
Repeated measures models will be used to compare changes in areal BMD at the spine, hip and femoral neck as well as spine trabecular bone score from DXA. Based on published results,6, 69 investigators anticipate the use of a spatial power covariance structure, with equal variances over time and within-subject correlations that are a decreasing function of the time between two measurements within an individual. They will consider other covariance structures, such as those induced by random effects models, if the spatial power covariance assumptions do not seem to hold. Contrasts within the repeated measures model will be used to make comparisons of the primary endpoints both overall and at specific time points. The analyses will be adjusted for age, height, race and ethnicity by including terms for these characteristics in the repeated measures model. Similar analyses will be done for the endpoints in hypotheses 1B and 1C. The analyses will be carried out primarily in SAS 9.4 PROC MIXED. Analysis of the Secondary Endpoint(s): The analyses for hypotheses 2A and 2B are similar to those of the primary endpoint. Contrasts will be used to make specific two-group comparisons of the changes in IGF-1 and SHBG between groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Disease other than FHA known to affect bone, including untreated thyroid dysfunction, Cushing's disease, renal failure, diabetes mellitus
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: transdermal 17β-E2 with cyclic progestin
Drug: oral 17β-E2 with cyclic progestin
Drug: transdermal EE+LNG
100-mcg transdermal 17β-E2 patch (to be applied twice weekly) (continuous use), with 200 mg micronized progesterone given for 12 days of every month
2 mg of oral 17β-E2 pills daily, with 200 mg micronized progesterone given for 12 days of every month
transdermal EE (30 mcg) + LNG (120 mcg) contraceptive patch (TWIRLA). Patch will be applied once a week for 3 consecutive weeks, with the 4th week off the patch (to be repeated after 4 weeks).
Areal BMD at the spine, hip and femoral neck as well as spine trabecular bone score from DXA
Using repeated measures analysis, the investigators will compare change in lumbar spine, total hip and femoral neck BMD and trabecular bone score after 12 months of treatment between the transdermal 17β-E2 group and each of the oral 17β-E2 and transdermal EE+LNG groups. BMD and TBS are assessed using DXA. Unit for BMD is g/cm2.
Time frame: Baseline and post-treatment (12 months)
12-month change in volumetric BMD at the radius and tibia
Using repeated measures analysis, the investigators will compare change in volumetric BMD at the radius and tibia after 12 months of treatment between the transdermal 17β-E2 group and each of the oral 17β-E2 and transdermal EE+LNG groups. Volumetric BMD is assessed using HRpQCT (mgHA/cm3)
Time frame: Baseline and post- treatment (12 months)
12-month change in cortical thickness at the radius and tibia
Using repeated measures analysis, the investigators will compare change in cortical thickness at the radius and tibia after 12 months of treatment between the transdermal 17β-E2 group and each of the oral 17β-E2 and transdermal EE+LNG groups. Cortical thickness is assessed using HRpQCT (mm).
Time frame: Baseline and post- treatment (12 months)
12-month change in failure load at the radius and tibia
Using repeated measures analysis, the investigators will compare change in failure load at the radius and tibia after 12 months of treatment between the transdermal 17β-E2 group and each of the oral 17β-E2 and transdermal EE+LNG groups. Failure load is assessed using microfinite element analysis (N).
Time frame: Baseline and post- treatment (12 months)
12-month change in IGF-1
Using repeated measures analysis, the investigators will compare change in IGF-1 concentrations after 12 months of treatment between the transdermal 17β-E2 group and the oral 17β-E2 group.
Time frame: Baseline and post-treatment (12 months)
12-month change in SHBG
Using repeated measures analysis, the investigators will compare change in SHBG concentrations after 12 months of treatment between the transdermal 17β-E2 group and the transdermal EE+LNG group
Time frame: Baseline and post-treatment (12 months)
Associations of 12-month change in IGF-1 with changes in P1NP
The investigators will use rank correlation analysis for this assessment.
Time frame: 12 months
Associations of 12-month change in SHBG with changes in P1NP
The investigators will use rank correlation analysis for this assessment.
Time frame: 12 months
Associations of 12-month change in P1NP with changes on bone endpoints
The investigators will use rank correlation analysis for this assessment.
Time frame: 12 monhts
Plan to share: Yes — Primary and secondary endpoint data, including all bone endpoints, will be submitted to the Harvard Dataverse repository to enable other researchers to analyze our study data independently. The privacy, rights, and confidentiality of human research participants will be protected by sharing only de-identified data.
Supporting information: Statistical analysis plan, Informed consent form
Time frame: Data sharing will occur no later than the end of performance period of the extramural award that generated the data. There is no end date planned at this time.
Access criteria: Study investigators will make access to deidentified data available via repository without restriction to access. Data available will include deidentified demographic data and those related to primary and secondary endpoints.
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Dec 2029, 50 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.